c-KIT expression enhances the leukemogenic potential of 32D cells

The Journal of Clinical Investigation
Q HuM D Minden

Abstract

The growth of human leukemic cells in culture and in vivo is dependent upon the presence of hematopoietic growth factors. Most populations of human leukemic acute myeloblastic leukemia (AML) cells express c-Kit on their surface and respond to Kit ligand (KL) in culture. To determine if this interaction was of potential significance in vivo we used a mouse model system. 32D cells, a murine IL-3-dependent myeloid cell line, were rendered KL responsive by transfection of the murine c-Kit. After injection of 32D or 32D-Kit cells into syngeneic hosts, animals bearing 32D-Kit cells, but not 32D cells, became moribund and were killed. These animals had circulating leukemic blast cells, infiltration of bone marrow, spleen, brain, liver, lung, and kidney. Cells recovered from some of the animals continued to be dependent upon IL-3 or KL for growth while in other cases the cells were factor independent. This model illustrates that the constitutive expression of c-Kit enhances the leukemic potential of 32D cells. The model will be useful for studying the progression of leukemia in vivo and testing whether interruption of the interaction of Kit and KL can affect the growth of leukemic cells.

References

Mar 1, 1992·The Journal of Clinical Investigation·H ChangM D Minden
Jan 1, 1990·Ciba Foundation Symposium·A BernsteinP Besmer
Oct 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·W MatthewsI R Lemischka
Mar 1, 1991·The Journal of Experimental Medicine·K MiyakeP W Kincade
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·F CozzolinoR Di Guglielmo
Nov 1, 1987·The Journal of Experimental Medicine·K SakaiK Takatsuki
Jul 1, 1983·Analytical Biochemistry·A P Feinberg, B Vogelstein
May 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·J S GreenbergerR J Eckner

❮ Previous
Next ❯

Citations

May 14, 2005·Cancer Immunology, Immunotherapy : CII·Adam T C CheukBarbara-ann Guinn
Jan 28, 1999·Leukemia Research·W S Alexander, N A Nicola
Feb 7, 2009·Leukemia & Lymphoma·Adam T C CheukBarbara-Ann Guinn
Apr 1, 1997·Leukemia & Lymphoma·A KimuraH Hyodo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.